MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Charles River Laboratories International Inc

Open

SectorGezondheidszorg

114.08 1.96

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

111.33

Max

115.8

Belangrijke statistieken

By Trading Economics

Inkomsten

-284M

-214M

Verkoop

-7.2M

1B

K/W

Sectorgemiddelde

513.35

57.333

EPS

2.66

Winstmarge

-21.32

Werknemers

18,700

EBITDA

-296M

-86M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+31.74% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3.4B

5B

Vorige openingsprijs

112.12

Vorige sluitingsprijs

114.08

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 aug 2024, 10:30 UTC

Top Nieuws

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Charles River Laboratories International Inc Prognose

Koersdoel

By TipRanks

31.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 152.5 USD  31.74%

Hoogste 188 USD

Laagste 100 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Charles River Laboratories International Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

12 ratings

0

Buy

12

Hold

0

Sell

Technische score

By Trading Central

99.95 / 116.06Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.